High-resolution imaging of the retina
Official title: High Resolution Retinal Imaging
Run by University of Pennsylvania · NCT01866371 · Data updated 2026-11-12
This study is testing a new way to take detailed pictures of the retina to help doctors better understand and treat eye diseases like Stargardt's and age-related macular degeneration in people aged 7 and older.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 7 Years and up |
| Sex | All |
| Enrollment | 600 (estimated) |
| Sponsor | University of Pennsylvania Academic / other |
| Locations | 1 site (Philadelphia, Pennsylvania) |
| Status | Recruiting |
| Started | May 2013 |
| Main results expected | December 2030 |
| Study ends | December 2031 |
| Registry record updated | May 5, 2026 |
| Trial ID | NCT01866371 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include males and females aged 7 years or older with or without retinal diseases.
✕Probably not a fit
Patients at risk for acute glaucoma, those who are photophobic, or individuals with significant ocular opacities may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study focuses on using adaptive optics scanning laser ophthalmoscopy (AOSLO) to capture high-resolution images of the retina in both healthy individuals and those with retinal diseases. By examining the morphology and function of the retina, the study aims to enhance the detection, diagnosis, and treatment of conditions such as Stargardt's disease, retinitis pigmentosa, and age-related macular degeneration. Participants aged 7 and older will undergo non-invasive retinal imaging, with a primary goal of identifying differences in retinal structure between affected and unaffected individuals. The study will involve case-control comparisons and will quantify changes in the cone photoreceptor mosaic and other retinal layers.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic techniques and treatment strategies for various retinal diseases.
How similar studies have gone: Other studies utilizing high-resolution retinal imaging techniques have shown promise in advancing our understanding of retinal diseases, indicating that this approach is both relevant and potentially impactful.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Males or females age 7 years or older. * Parental/guardian permission (informed consent) and if appropriate, child assent. Child subjects age 7-17 must give assent. * Reasonable compliance with an imaging protocol as determined by the study personnel. Exclusion Criteria: * Individuals that are at risk to acute glaucoma. * Individuals that are photophobic and experience adverse psychological reactions to flashes of light. * Ocular opacities, high refractive error, and high frequency of nystagmus as determined by the study team.
Where it's running
-
University of Pennsylvania
Philadelphia, Pennsylvania, United States Recruiting
Study contacts
- Principal investigator: Jessica IW Morgan, PhD — University of Pennsylvania
- Study coordinator: Jessica IW Morgan, PhD
- Email: jwmorgan@pennmedicine.upenn.edu
- Phone: 215-614-4196
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Understanding Age-Related Macular Degeneration and Its Progression
This study looks at how age-related macular degeneration develops and progresses by comparing people with the condition to healthy individuals, using non-invasive tests and personal feedback.
-
C.001 for retinal degeneration: a first-in-human dose-escalation safety test
A first-in-human study will test the safety and tolerability of a single subretinal injection of C.001 in adults with retinal diseases involving retinal pigment epithelium degeneration.
-
Central microperimetry and radial OCT in geographic atrophy
We will test whether central microperimetry and radial OCT scans can more accurately measure how geographic atrophy progresses toward the fovea in people with or at risk for GA from age-related macular degeneration.
-
Eye injections of ABBV-6628 for geographic atrophy from age-related macular degeneration
This trial will test whether intravitreal ABBV-6628 is safe and how the drug moves through the body in adults aged 50 and older with geographic atrophy from AMD.
-
Evaluating a stem cell treatment for geographic atrophy from dry age-related macular degeneration.
This study is testing a new stem cell treatment for people with geographic atrophy from dry age-related macular degeneration to see if it can help improve their vision.
-
Assessing vision measurement methods for patients with retinal degeneration
This study is testing different ways to measure vision in people with retinal degeneration to see how their eyesight affects daily life and how it changes over time.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.